换一批Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial.
第一作者：
Anja,Rinke
第一单位：
Department of Gastroenterology and Endocrinology, Philipps University of Marburg, Marburg, Germany, sprengea@uni-marburg.de.
作者：
医学主题词
老年人(Aged);迟效制剂(Delayed-Action Preparations);无病生存(Disease-Free Survival);双盲法(Double-Blind Method);女(雌)性(Female);随访研究(Follow-Up Studies);德国(Germany);人类(Humans);肠肿瘤(Intestinal Neoplasms);男(雄)性(Male);中年人(Middle Aged);肿瘤转移(Neoplasm Metastasis);神经内分泌瘤(Neuroendocrine Tumors);奥曲肽(Octreotide);安慰剂(Placebos);生活质量(Quality of Life)
DOI
10.1159/000499469
PMID
30852564
发布时间
2020-06-01
- 浏览6
Neuroendocrinology
141-151页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
